Prescribing cholinesterase inhibitors in mild cognitive impairment—Observations from the Alzheimer's Disease Neuroimaging Initiative
Abstract
Analyses of off‐label use of acetylcholinesterase inhibitors (AChEIs) in mild cognitive impairment (MCI) has produced mixed results. Post hoc analyses of observational cohorts, such as the Alzheimer's Disease Neuroimaging Initiative (ADNI), have reported deleterious effects in AChEI‐treated subjects (AChEI+). Here, we used neuroimaging biomarkers to determine whether AChEI+ subjects had a greater rate of neurodegeneration than untreated (AChEI–) subjects while accounting for baseline differences.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Jan 01, 2021
- Source ID
- 10.1002/trc2.12168
Entities
People
- Andrew J. Saykin
- Diana O Svaldi
- Eddie Stage
- For The Alzheimer’s Disease Neuroimaging Initiative*
- Jerome I Rotter
- Krisztina Marosi
- Liana G. Apostolova
- Shannon L. Risacher
- Sophie Sokolow
Organizations
- Indiana University School of Medicine
- National Institute of Biomedical Imaging and Bioengineering
- National Institute on Aging
- National Institutes of Health
- United States Department of Defense
- University of California, Los Angeles